

PUBLISHED VERSION

Carmel T Collins, Robert A Gibson, Peter J Anderson, Andrew J McPhee, Thomas R Sullivan, Jacqueline F Gould, Philip Ryan, Lex W Doyle, Peter G Davis, Judy E McMichael, Noel P French, Paul B Colditz, Karen Simmer, Scott A Morris, Maria Makrides

Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial

BMJ Open, 2015; 5(3):e007314-1-e007314-11

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Originally published by BMJ –

<http://dx.doi.org/10.1136/bmjopen-2014-007314>

PERMISSIONS

<http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse>

The BMJ's open access articles are all the research articles that we publish (irrespective of who funded the research) and any other article based on work funded by a funding organisation that requires open access publication—that is, requires its grant recipients to deposit publications arising out of the funded work to be deposited in PubMed Central open access repository.

By default, we publish these articles under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence that allows reuse subject only to the use being non-commercial and to the article being fully attributed (<http://creativecommons.org/licenses/by-nc/4.0/>). Articles funded by certain organisations (currently RCUK and the Wellcome Trust) that mandate publication with a Creative Commons Attribution (CC BY 4.0) licence, which permits reuse for commercial purposes subject to the article being fully attributed (<http://creativecommons.org/licenses/by/4.0/>) are published with this licence. *The BMJ* makes all open access articles freely available on thebmj.com from the date of publication and at the same time sends them to PubMed Central (see below).

12 August 2014

<http://hdl.handle.net/2440/91697>

BMJ Open Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial

Carmel T Collins,^{1,2,3,4} Robert A Gibson,^{1,2,4} Peter J Anderson,^{5,6} Andrew J McPhee,^{2,3,7} Thomas R Sullivan,⁸ Jacqueline F Gould,^{1,4} Philip Ryan,⁸ Lex W Doyle,^{5,6,9} Peter G Davis,^{5,9} Judy E McMichael,^{10,11} Noel P French,^{10,11} Paul B Colditz,¹² Karen Simmer,^{10,11} Scott A Morris,¹³ Maria Makrides^{1,2,3,4}

To cite: Collins CT, Gibson RA, Anderson PJ, *et al*. Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial. *BMJ Open* 2015;5:e007314. doi:10.1136/bmjopen-2014-007314

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-007314>).

Received 27 November 2014
Revised 21 February 2015
Accepted 24 February 2015



CrossMark

For numbered affiliations see end of article.

Correspondence to

Professor Maria Makrides;
maria.makrides@health.sa.gov.au

ABSTRACT

Objective: To determine if improvements in cognitive outcome detected at 18 months' corrected age (CA) in infants born <33 weeks' gestation receiving a high-docosahexaenoic acid (DHA) compared with standard-DHA diet were sustained in early childhood.

Design: Follow-up of a multicentre randomised controlled trial. Randomisation was stratified for sex, birth weight (<1250 vs ≥1250 g) and hospital.

Setting: Five Australian tertiary hospitals from 2008 to 2013.

Participants: 626 of the 657 participants randomised between 2001 and 2005 were eligible to participate.

Interventions: High-DHA (≈1% total fatty acids) enteral feeds compared with standard-DHA (≈0.3% total fatty acids) from age 2–4 days until term CA.

Primary outcome: Full Scale IQ of the Wechsler Abbreviated Scale of Intelligence (WASI) at 7 years CA. Prespecified subgroup analyses based on the randomisation strata (sex, birth weight) were conducted.

Results: 604 (92% of the 657 originally randomised) consented to participate (291 high-DHA, 313 standard-DHA). To address missing data in the 604 consenting participants (22 for primary outcome), multiple imputation was performed. The Full Scale IQ was not significantly different between groups (high-DHA 98.3, SD 14.0, standard-DHA 98.5, SD 14.9; mean difference adjusted for sex, birthweight strata and hospital –0.3, 95% CI –2.9 to 2.2; *p*=0.79). There were no significant differences in any secondary outcomes. In prespecified subgroup analyses, there was a significant sex by treatment interaction on measures of parent-reported executive function and behaviour. Scores were within the normal range but girls receiving the high-DHA diet scored significantly higher (poorer outcome) compared with girls receiving the standard-DHA diet.

Conclusions: Supplementing the diets of preterm infants with a DHA dose of approximately 1% total fatty acids from days 2–4 until term CA showed no evidence of benefit at 7 years' CA.

Strengths and limitations of this study

- First study to evaluate the effect a diet that provides the estimated in utero accretion rate of docosahexaenoic acid in infancy has on neurodevelopmental outcomes in early childhood.
- Sample size large enough to detect a four-point difference in Full Scale IQ if it existed.
- Low risk of bias achieved through minimal attrition rate (92% of children originally randomised consented to participate) and blinding of research personnel, outcome assessors and all but 12 families.
- Robust objective assessments of neurodevelopmental outcomes undertaken by psychologists after extensive training and ongoing auditing.
- A limitation of the study was not including a teacher assessment of the child's behaviour.

Trial registration number: Australian New Zealand Clinical Trials Registry: ACTRN12606000327583.

INTRODUCTION

With advances in clinical care, increasing numbers of very preterm infants are surviving into childhood. However, neurobehavioural impairments have not decreased, imposing an increasing burden on health and education systems. There remains an inverse relationship between cognitive functioning and gestational age, with the most preterm survivors being most affected by poor cognitive functioning.¹

The long chain polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6 n-3) is a

major lipid in the brain and is known to be involved in neurogenesis and neurite growth.² Infants born very preterm are deprived of the placental supply of DHA that occurs in the last trimester of pregnancy and have lower brain concentrations of DHA than term-born infants,³ possibly contributing to their high risk of developmental delay. The only trials where the dose of DHA has matched the estimated in utero accretion rate of DHA (≈ 45 mg/kg/day)⁴ and was inclusive of breast milk feeding have shown some short-term benefit of DHA supplementation.^{5–7} The DHA for the Improvement of Neurodevelopmental Outcome in preterm infants (DINO) trial is the largest published trial of DHA supplementation in very preterm infants.⁶ The DINO trial showed that although mean cognitive development at 18 months' corrected age (CA) was not altered overall, the proportion of infants with severe developmental delay was significantly reduced. In prespecified subgroup analyses, the greatest effect was seen in girls and there was a strong suggestion of benefit in the smallest infants.⁶

Assessing neurodevelopment within the first 2 years of life remains a cornerstone of preterm infant follow-up ensuring early detection of problems and initiation of appropriate support services. However, developmental outcomes measured in the first 2 years may not accurately predict a longer term developmental outcome.^{8,9} Related to this, some cognitive domains that are hypothesised to be influenced by DHA, such as executive function and memory, are difficult to reliably assess in early childhood. We therefore aimed to determine the effect of DHA given up to term equivalent to infants born less than 33 weeks' gestation, on neurodevelopment at 7 years' CA.

METHODS

This is a follow-up at 7-years' CA of infants who participated in the DINO randomised controlled trial.

Initial study—the DINO trial

The DINO trial methods have been previously published.⁶ Between 2001 and 2005, 657 infants born <33 weeks' gestation from five Australian tertiary hospitals were randomised, from within 5 days of their first enteral feed, to receive a high-DHA or standard-DHA diet until 40 weeks' CA. Infants were excluded if they had a major congenital or chromosomal abnormality, were from a multiple birth in which not all live-born infants were eligible, were in other trials of fatty acid supplementation, or if fish oil was contraindicated in the lactating mother. Mother–infant pairs were randomly assigned a unique study number using a computer-driven telephone randomisation service according to an independently generated randomisation schedule. Stratification was by centre, birth weight (<1250 and ≥ 1250 g) and infant sex. Multiple births were considered a single randomisation unit. Participants were enrolled and assigned to their study group by research nurses at each centre.

Dietary treatments

Lactating women with infants randomised to the high-DHA group took DHA-rich tuna oil capsules daily to achieve a breast milk DHA concentration $\approx 1\%$ of total fatty acids without altering the naturally occurring concentration of arachidonic acid. Infants requiring formula received a high-DHA preterm formula ($\approx 1.0\%$ DHA and $\approx 0.6\%$ AA). The high-DHA diet provided ≈ 50 mg/kg/day of DHA. Lactating women with infants randomised to standard-DHA took placebo soy oil capsules. Infants requiring formula received standard preterm infant formula ($\approx 0.35\%$ DHA). The standard-DHA diet provided ≈ 20 mg/kg/day of DHA. Postdischarge, women who were breast feeding were encouraged to continue, and those using formula were encouraged to use a commercially available term formula supplemented with DHA. Parents, clinicians and all research personnel were blinded to the participant study group.

Present study—follow-up at 7 years' CA

The parent or guardian of each participant provided written informed consent. A letter of invitation was sent to caregivers of eligible children followed by a telephone call. Of the 657 infants randomised to the DINO trial, 626 children were eligible to participate in the 7-year CA follow-up (ie, had not withdrawn from the study or died). Clinicians and researchers remained unaware of group allocations; the statistician was unblinded during the 18-month CA analysis of the DINO results. Twelve families (6 children in each group) requested to be unblinded after publication of the 18-month CA results. Assessments were administered by trained psychologists blinded to group allocation and the 18-month CA assessment results. Assessments were conducted at the participating perinatal centre; if this was unsuitable for the family, assessments were conducted elsewhere. The assessment, including short breaks, took 3 h and was conducted within ± 3 months of the 7-year CA date. In difficult to locate families, efforts to conduct an assessment continued beyond this age. The child's CA (chronological age reduced by the number of weeks born before 40 weeks of gestation) was used to calculate age-standardised test scores, thus avoiding a known bias in cognitive scores which we have reported to be clinically important at all ages through childhood.¹⁰

Primary outcome

The primary outcome was general intellectual ability as assessed by the Full Scale IQ of the Wechsler Abbreviated Scale of Intelligence (WASI). The WASI consists of four subtests (Vocabulary, Similarities, Block Design and Matrix Reasoning) and provides a brief and reliable estimate of the child's intellectual functioning. These four subtests yield the Full Scale IQ which is age standardised with a mean of 100 (SD 15). In the event that children had a recent Full Scale IQ assessment using a different psychological test, the results from that test were used.

Secondary outcomes

Secondary outcomes included cognitive domains that have been previously demonstrated to be areas of concern for preterm children, as well as those domains thought to be sensitive to DHA depletion and included intellectual impairment, Verbal and Performance IQ, attention, memory and learning, executive functioning, behaviour, visual-spatial perceptual skills, educational progress and quality of life. Intellectual impairment, assessed using the WASI Full Scale IQ, was defined as mild (IQ <85) and major (IQ <70). Verbal and performance IQ scores were acquired from the WASI. Subtests of the Test of Everyday Attention for Children measured selective attention (Sky Search), sustained attention (Score!), shifting attention/attentional control (Creature Counting) and divided attention (Sky Search Dual Task).¹¹ The score for Divided Attention was calculated by multiplying the proportion of visual stimuli found by the proportion of auditory stimuli counted, multiplied by 10 (with 10 signifying a perfect score).¹² Aspects of executive functioning were assessed with the Rey Complex Figure, the Fruit Stroop Test and the parent-completed Behaviour Rating Inventory of Executive Functioning (BRIEF).

Short-term verbal memory and learning were assessed with the Rey Auditory Verbal Learning Test. Visual Perception was assessed with the Visual-Spatial Relations, Visual Figure-Ground and Visual Closure subtests of the Test of Visual Perceptual Skills, third edition. Educational progress was assessed with the Word Reading, Spelling, and Math Computation subtests of the Wide Range Achievement Test fourth edition. Parents were also questioned on whether their child had repeated a year at school.

Child behaviour was assessed with two parent-completed questionnaires; the Conners 3rd Edition ADHD Index (Conners 3 AI-parent) which screens for Attention Deficit Hyperactivity Disorder (ADHD), and the Strengths and Difficulties Questionnaire which screens for emotional and behaviour problems. General health status and health-related quality of life were measured using parent-completed questionnaires: the Multi-attributed Health Status Classification System—Health Utilities Index Mark 3 and the Pediatric Quality of Life Inventory.

Information on family functioning (Family Assessment Device), and recent family events (Recent Life Events Questionnaire) were collected through parent-completed questionnaires. General child health, home environment, DHA containing diet and supplement use were collected.

If the child was unable to complete an assessment due to severe developmental delay, they were assigned the lowest possible score. Outcome scores were recorded as missing if the child was uncooperative or they were untestable due to a motor or sensory impairment.

SAMPLE SIZE AND STATISTICAL ANALYSIS

This follow-up study was designed in 2007 before the 18-month CA assessments had been completed. We

anticipated a follow-up rate of at least 90% at 7 years, that is, >590 children (295 per group). Using blinded 18-month Mental Development Index results available at the time, we estimated that the design effect due to the non-independence of multiple births was 1.14 (intraclass correlation coefficient (ICC)=0.70, average of 1.20 infants per mother), giving an effective sample size of 259 children per group at 7 years. With these assumptions, we had 85% power ($\alpha=0.05$) to detect a four-point minimum difference in the Full Scale IQ scores (SD 15) between groups. In prespecified subgroup analyses by randomisation strata (sex and birth weight <1250 g), we had 85% power ($\alpha=0.05$) to detect a six-point difference (SD 15).

Data management and analysis

All participants who consented to participate in the 7-year CA follow-up (whether they completed the assessments or not) were analysed according to the group to which they were allocated. To address missing outcome data, multiple imputation was performed separately by treatment group using chained equations¹³ to create 100 complete data sets, under the assumption that data were missing at random. Imputation models included covariates prespecified for adjustment and auxiliary variables that helped to satisfy the missing at random assumption or that were predictive of outcomes. Following analysis, the effect estimates from the imputed data sets were combined using Rubin's rules.¹⁴ The primary analysis was based on imputed data and included all participants who consented to the follow-up study. Sensitivity analyses were performed on the available data and on imputed data for the 657 children in the original sample, excluding deaths. All analyses produced similar results and only the results of the primary analysis are presented.

Outcomes were analysed using generalised estimating equations (GEE) to account for clustering due to multiple births. Normally distributed outcomes were analysed using a linear GEE, with the effect of treatment expressed as a mean difference with 95% CI. Binary outcomes were analysed using log-binomial GEE, with the effect of treatment expressed as a relative risk (RR) with 95% CI. Unadjusted and adjusted analyses were performed, with adjustment for the stratification variables (centre, birth weight, sex). Statistical significance was assessed at the two-sided $p<0.05$ level. All analyses followed a prespecified statistical analysis plan and were performed using SAS V.9.3 (Cary, North Carolina, USA) and Stata Release V.12 (Statacorp LP, College Station, Texas, USA).

RESULTS

Study participants

The participant flow for infants randomly assigned to receive the high-DHA or standard-DHA diet and assessed at 7 years' CA is shown in the [figure 1](#). Follow-up assessments began in June 2008 and ended on 10 July 2013. In total, 604 families consented to participate in the 7-year




Figure 1 DINO trial participant flow in the 7-year follow-up. CA, corrected age; DHA, docosahexaenoic acid; DINO, Docosahexaenoic acid for the Improvement of Neurodevelopmental Outcome in preterm infants; EDD, expected date of delivery.

follow-up (92% of the 657 originally randomised). Adequate data for analysis of the primary outcome (Full Scale IQ) were available for 582 (89%) of the 657 randomised children and 93% of the 626 children eligible for the 7-year follow-up (high-DHA n=286, standard-DHA n=296; [figure 1](#)). Twenty children (high-DHA n=8, standard-DHA n=12) were assessed using a different IQ measure (Wechsler Preschool and Primary Scale of Intelligence n=17; Wechsler Intelligence Scale for Children n=2; or Differential Ability Scales n=1) because of their involvement in other studies.

The characteristics of the 604 children consenting to follow-up were similar at randomisation ([table 1](#)). Two children (both in the standard-DHA group) died between 18 months' and 7 years' CA ([table 2](#)); their deaths were reviewed by an independent Mortality Review Committee blinded to treatment group and deemed to be unrelated to the study product or protocol. Children were assessed at a mean of 7.2 years' CA ([table 2](#)). Family functioning and life events affecting the children were similar between groups based on scores from the Family Assessment Device and Recent Life Events ([table 2](#)). English was the primary language spoken at home for the majority of children and the consumption of DHA containing foods or supplements was similar between groups ([table 2](#)).

Primary outcome at 7 years' CA

The Full Scale IQ was not significantly different between the two groups (high-DHA 98.3, SD 14.0, standard-DHA 98.5, SD 14.9; mean difference adjusted for sex, birth weight (<1250 or ≥1250 g) and the recruiting centre -0.3, 95% CI -2.9 to 2.2; p=0.79) ([table 3](#)).

Secondary outcomes at 7 years' CA

Intellectual impairment, that is, a Full Scale IQ <85 or <70 did not differ significantly between the groups ([table 3](#)),

Table 1 Baseline (at randomisation) clinical and demographic characteristics

	High-DHA diet (n=291)	Standard-DHA diet (n=313)
Median (IQR) gestational age (weeks)	30.0 (28.0–31.0)	30.0 (28.0–31.0)
Mean (SD) birth weight (g)	1307 (420)	1320 (410)
Male sex	152 (52.2)	172 (55.0)
Singleton birth	208 (71.5)	195 (62.3)
Birth weight <1250 g	132 (45.4)	139 (44.4)
Birth weight <10th centile*	54 (18.6)	57 (18.2)
Mean (SD) birth length (cm) (n=222/238)†	38.2 (3.9)	38.2 (4.1)
Mean (SD) birth head circumference (cm) (n=248/261)†	27.2 (2.8)	27.4 (2.7)
Mean (SD) maternal age (years)	29.9 (5.7)	30.5 (5.2)
Mother smoked during pregnancy	77 (26.5)	76 (24.3)
Infant received breast milk at trial entry	271 (93.1)	291 (93.0)
Mother completed secondary education (n=280/293)†	175 (62.5)	172 (58.7)
Father completed secondary education (n=270/280)†	146 (54.1)	155 (55.4)

Values are numbers (percentage) of infants unless stated otherwise.

*The 10th centile for gestational age in a normal population as reported by Cole *et al.*³¹

†Numerical data available for high-DHA and standard-DHA, respectively.

DHA, docosahexaenoic acid.

Table 2 Postrandomisation treatment group comparison of demographic, social and clinical characteristics

	High-DHA diet (n=291)	Standard-DHA diet (n=313)	p Value
Social variables			
Mean, SD corrected age at primary outcome assessment, years (n=284/293)	7.2 (0.4)	7.2 (0.3)	0.69
Death between 18 months and 7 years' corrected age (n=313/326*)	0 (0.0)	2 (0.6)	0.50†
Family unblinded before the 7-year corrected age assessment	6 (2.1)	6 (1.9)	>0.99
English primary language spoken at home (n=285/298)	278 (97.5)	296 (99.3)	0.10
Living in two parent family‡ (n=285/298)	214 (75.1)	237 (79.5)	0.23†
Mean (SD) Recent Life Events, total events (n=278/290)	2.5 (2.5)	2.2 (2.4)	0.20
Mean (SD) Recent Life Events, total events still impacting (n=278/290)	0.5 (1.2)	0.4 (1.0)	0.47
Mean (SD) Family Assessment Device general functioning score (n=278/289)	1.6 (0.4)	1.5 (0.4)	0.24
Dietary variables			
Had fish in the last month (n=285/298)	248 (87.0)	267 (89.6)	0.39
Mean (SD) number of fish meals in the last month (n=246/266)	5.0 (3.8)	5.1 (3.6)	0.96
Had DHA-enriched foods in the last month (n=285/298)	172 (60.4)	181 (60.7)	0.93
Mean (SD) number of DHA-enriched foods in the last month (n=164/173)	21.2 (26.4)	16.8 (18.2)	0.16
Had a supplement containing DHA in the last month (n=283/293)	73 (25.8)	57 (19.5)	0.10

Values are numbers (percentage) of infants unless stated otherwise.

*Denominator based on randomised infants still alive at the completion of DINO.

†Fisher exact p Value.

‡Families with biological parents living together and new marriage/de facto relationship.

DHA, docosahexaenoic acid; DINO, DHA for the Improvement of Neurodevelopmental Outcome in preterm infants trial.

and nor did the Verbal and Performance IQ scores (table 3). There was no effect of the high-DHA diet on selective, sustained, shifting or divided attention, short-term verbal memory or learning ability, executive functioning, visual perception or academic achievement (table 4).

According to parental reports, there were no differences between the high-DHA and standard-DHA groups in executive functioning, ADHD symptoms, emotional and behaviour problems, general health status, health-related quality of life or in the percentage of children repeating a school year (table 5). The parent-reported health-related quality of life neared 'perfect health' (score of 1) for both groups. Furthermore, parental reports of a diagnosis of ADHD

(high-DHA 9/285, 3.2%; standard-DHA 7/298, 2.3%; RR=1.34, 95% CI 0.51 to 3.56; p=0.55), ADHD and using medication (high-DHA 6/285, 2.1%; standard-DHA 4/298, 1.3%; RR=1.57, 95% CI 0.45 to 5.50; p=0.48) autism spectrum disorder (high-DHA 10/285, 3.5%; standard-DHA 9/298, 3.0%; RR=1.16, 95% CI 0.48 to 2.82; p=0.74) or cerebral palsy (high-DHA 14/285, 4.9%; standard-DHA 9/298, 3.0%; RR=1.63, 95% CI 0.72 to 3.70; p=0.25) did not differ significantly between groups.

Subgroup analysis by randomisation strata—sex

There was no interaction effect between dietary treatment and sex for the primary outcome Full Scale IQ (see web appendix A).

Table 3 Primary and secondary outcomes from the Wechsler Abbreviated Scale of Intelligence* at 7 years' corrected age

Outcome	High-DHA diet mean (SD) N=291	Standard-DHA diet mean (SD) N=313	Unadjusted treatment effect (95% CI)	Unadjusted p Value	Adjusted treatment effect (95% CI)†	Adjusted p Value‡
Primary						
Full Scale IQ	98.3 (14.0)	98.5 (14.9)	-0.3 (-2.9 to 2.4)	0.85	-0.3 (-2.9 to 2.2)	0.79
Secondary						
Verbal IQ	98.0 (14.2)	98.8 (15.8)	-0.7 (-3.5 to 2.0)	0.59	-0.9 (-3.5 to 1.8)	0.52
Performance IQ	98.5 (14.5)	98.5 (13.6)	0.0 (-2.5 to 2.6)	0.98	-0.0 (-2.5 to 2.5)	0.99
Number (%) Full Scale IQ <85‡	40 (13.6)	44 (14.1)	1.0 (0.6 to 1.5)	0.87	1.0 (0.6 to 1.5)	0.84
Number (%) Full Scale IQ <70§ (n=286/296)	3 (1.0)	5 (1.7)		0.73		

Values are mean (SD) and treatment effects are mean difference based on imputed data unless otherwise indicated.

*Wechsler Abbreviated Scale of Intelligence IQ, the mean (SD) score is 100 (15), range 50–160.

†Adjusted for sex, birth weight (<1250 or ≥1250 g) and recruiting centre.

‡Treatment effect is relative risk.

§Raw data used due to the small number of cases; compared using the Fisher exact test.

DHA, docosahexaenoic acid.

Table 4 Secondary developmental outcomes

Outcome	High-DHA diet mean (SD) N=291	Standard-DHA diet mean (SD) N=313	Unadjusted mean difference (95% CI)	Unadjusted p Value	Adjusted difference (95% CI)*	Adjusted p Value*
Test of Everyday Attention for Children†						
Sky search number correct scale score‡	8.9 (3.7)	8.9 (3.8)	0.0 (-0.6 to 0.7)	0.96	0.0 (-0.6 to 0.7)	0.89
Score! number correct scale score§	8.1 (3.8)	8.0 (3.6)	0.1 (-0.6 to 0.7)	0.79	0.1 (-0.6 to 0.7)	0.79
Creature counting number correct scale score¶	7.7 (3.6)	8.0 (3.4)	-0.3 (-0.9 to 0.3)	0.36	-0.3 (-0.9 to 0.3)	0.36
Sky search dual task composite score**						
Rey Auditory Verbal Learning Test††	4.2 (2.8)	4.4 (2.9)	-0.1 (-0.6 to 0.4)	0.67	-0.1 (-0.6 to 0.4)	0.66
Trial 1 correct words						
Total (trials 1-5) correct words	4.4 (2.0)	4.3 (2.0)	0.1 (-0.3 to 0.4)	0.71	0.1 (-0.3 to 0.4)	0.68
Total intrusions	34.4 (12.1)	34.8 (10.8)	-0.4 (-2.3 to 1.6)	0.71	-0.3 (-2.2 to 1.5)	0.72
Total repetitions	2.1 (3.5)	2.5 (4.0)	-0.4 (-1.0 to 0.3)	0.25	-0.4 (-1.0 to 0.3)	0.25
Delayed recall correct words	4.0 (4.5)	3.7 (4.1)	0.3 (-0.4 to 1.0)	0.45	0.3 (-0.4 to 1.0)	0.44
Delayed recognition correct words	7.3 (3.5)	7.2 (3.0)	0.2 (-0.4 to 0.7)	0.58	0.1 (-0.4 to 0.7)	0.57
Rey Complex Figure‡‡						
Copy raw score	13.3 (2.6)	13.1 (3.0)	0.2 (-0.3 to 0.6)	0.50	0.2 (-0.3 to 0.6)	0.50
Delayed recall raw score	16.6 (7.4)	16.3 (7.8)	0.3 (-1.0 to 1.6)	0.66	0.3 (-0.9 to 1.6)	0.61
Organisational raw score	7.6 (4.9)	7.0 (5.0)	0.6 (-0.3 to 1.4)	0.18	0.6 (-0.2 to 1.4)	0.17
Fruit Stroop Test§§	3.4 (1.2)	3.3 (1.2)	0.1 (-0.1 to 0.3)	0.57	0.1 (-0.1 to 0.3)	0.52
Interference score						
Test of Visual Perception Skills third edition¶¶	1.0 (5.8)	1.1 (5.4)	-0.2 (-1.1 to 0.8)	0.75	-0.2 (-1.1 to 0.8)	0.75
Visual discrimination standard score						
Figure ground standard score	8.1 (3.1)	8.1 (3.6)	-0.0 (-0.6 to 0.5)	0.95	-0.0 (-0.6 to 0.5)	0.96
Visual closure standard score	9.4 (3.8)	9.6 (4.3)	-0.2 (-0.9 to 0.5)	0.62	-0.2 (-0.9 to 0.5)	0.55
Wide Range Achievement Test fourth edition***						
Word reading standard score	7.6 (3.6)	8.0 (3.7)	-0.4 (-1.1 to 0.2)	0.15	-0.4 (-1.1 to 0.2)	0.16
Spelling standard score	102.2 (16.0)	101.5 (18.4)	0.8 (-2.2 to 3.8)	0.62	0.6 (-2.4 to 3.6)	0.68
Math computation standard score	97.5 (16.4)	98.0 (17.1)	-0.5 (-3.4 to 2.4)	0.74	-0.7 (-3.5 to 2.2)	0.65
	90.8 (15.0)	90.6 (15.0)	0.2 (-2.5 to 2.9)	0.88	0.2 (-2.4 to 2.8)	0.87

Values are mean (SD) and treatment effects are mean difference based on imputed data unless otherwise indicated.

*Adjusted for sex, birth weight (<1250 or ≥1250 g) and recruiting centre.

†Measures attention; the mean scale score is 10, range 8-12; an attention scale score of less than 8 is indicative of poor attention; the composite score is not standardised.

‡Selective attention measure.

§Sustained attention measure.

¶Attentional control measure.

**Divided attention measure.

††Measures executive function (verbal learning memory).

‡‡Measures executive function (visuospatial abilities and visuospatial memory).

§§Measures executive function (inhibitory control).

¶¶Measures visual perceptual skills; the mean (SD) score is 10 (3), range 8-12; a score of less than 8 indicates poor visual perceptual skills.

***Measures educational progress; the mean (SD) score is 100 (15).

DHA, docosahexaenoic acid.

Table 5 Parent-reported health, well-being and education outcomes.

Outcome	High-DHA diet mean (SD) N=291	Standard-DHA diet mean (SD) N=313	Unadjusted mean difference (95% CI)	Unadjusted p Value	Adjusted mean difference (95% CI)*	Adjusted p Value*
BRIEF†						
Behavioural regulation index	53.7 (12.4)	51.8 (12.5)	1.9 (-0.3 to 4.1)	0.09	1.9 (-0.3 to 4.0)	0.09
Inhibit scale	53.3 (11.4)	51.6 (11.5)	1.8 (-0.2 to 3.8)	0.08	1.7 (-0.2 to 3.7)	0.09
Shift scale	53.6 (13.0)	51.7 (12.6)	1.9 (-0.3 to 4.1)	0.10	1.8 (-0.4 to 4.0)	0.10
Emotional control scale	53.2 (12.3)	51.8 (12.7)	1.4 (-0.8 to 3.5)	0.23	1.3 (-0.8 to 3.5)	0.23
Metacognition index	54.9 (12.6)	53.9 (12.8)	0.9 (-1.3 to 3.1)	0.43	0.8 (-1.4 to 3.0)	0.48
Initiate scale	53.1 (11.6)	52.4 (11.6)	0.7 (-1.3 to 2.8)	0.49	0.6 (-1.4 to 2.7)	0.54
Working memory scale	55.5 (13.4)	55.1 (13.7)	0.4 (-1.9 to 2.7)	0.75	0.3 (-2.0 to 2.5)	0.81
Plan/organise scale	56.0 (13.4)	55.4 (13.3)	0.6 (-1.7 to 3.0)	0.61	0.5 (-1.8 to 2.8)	0.67
Organisation of materials scale	53.1 (10.7)	52.1 (10.9)	1.1 (-0.8 to 3.0)	0.27	1.0 (-0.9 to 2.9)	0.28
Monitor scale	53.0 (12.8)	52.4 (13.1)	0.6 (-1.6 to 2.9)	0.58	0.5 (-1.7 to 2.7)	0.64
Global executive composite (total score)	55.0 (12.5)	53.6 (12.9)	1.4 (-0.9 to 3.6)	0.24	1.3 (-1.0 to 3.5)	0.26
ADHD (Conners 3 AI-parent)‡						
ADHD t score (total score)	65.6 (18.5)	64.4 (18.7)	1.3 (-1.9 to 4.4)	0.43	1.1 (-2.0 to 4.2)	0.47
Strengths and Difficulties Questionnaire§						
Emotional symptoms score	2.4 (2.2)	2.3 (2.1)	0.2 (-0.2 to 0.6)	0.33	0.2 (-0.2 to 0.5)	0.35
Conduct problems score	2.1 (1.9)	1.9 (1.8)	0.2 (-0.1 to 0.5)	0.20	0.2 (-0.1 to 0.5)	0.18
Hyperactivity score	4.4 (2.8)	4.3 (2.8)	0.1 (-0.4 to 0.6)	0.72	0.1 (-0.3 to 0.6)	0.66
Peer problems score	1.8 (1.9)	1.6 (1.7)	0.2 (-0.1 to 0.5)	0.16	0.2 (-0.1 to 0.5)	0.16
Prosocial Behaviour score	8.2 (1.9)	8.1 (2.0)	0.1 (-0.2 to 0.4)	0.52	0.1 (-0.2 to 0.4)	0.52
Impact score	0.9 (1.9)	0.9 (1.7)	0.0 (-0.3 to 0.3)	0.86	0.0 (-0.3 to 0.3)	0.82
Total Difficulties score	10.8 (6.7)	10.1 (6.2)	0.7 (-0.4 to 1.8)	0.22	0.7 (-0.4 to 1.8)	0.21
Health Utilities Index Mark 3¶						
Vision score	0.98 (0.06)	0.98 (0.08)	0.00 (-0.01 to 0.01)	0.84	0.00 (-0.01 to 0.01)	0.89
Hearing score	1.00 (0.03)	1.00 (0.04)	-0.00 (-0.01 to 0.00)	0.71	-0.00 (-0.01 to 0.00)	0.75
Speech score	0.96 (0.12)	0.94 (0.14)	0.02 (-0.00 to 0.04)	0.12	0.02 (-0.00 to 0.04)	0.12
Ambulation score	0.98 (0.11)	0.99 (0.09)	-0.01 (-0.02 to 0.01)	0.39	-0.01 (-0.02 to 0.01)	0.35
Dexterity score	0.99 (0.09)	0.99 (0.09)	-0.00 (-0.02 to 0.01)	0.79	-0.00 (-0.02 to 0.01)	0.76
Emotion score	0.99 (0.04)	0.99 (0.03)	-0.01 (-0.01 to 0.00)	0.10	-0.01 (-0.01 to 0.00)	0.10
Cognition score	0.93 (0.14)	0.94 (0.13)	-0.01 (-0.03 to 0.01)	0.51	-0.01 (-0.03 to 0.01)	0.47
Pain score	0.99 (0.06)	0.99 (0.03)	-0.01 (-0.01 to 0.00)	0.13	-0.01 (-0.01 to 0.00)	0.13
Overall score	0.89 (0.18)	0.90 (0.17)	-0.01 (-0.04 to 0.02)	0.46	-0.01 (-0.04 to 0.02)	0.43
Paediatric Quality of Life Inventory**						
Physical functioning score	87.2 (17.6)	87.7 (17.1)	-0.5 (-3.4 to 2.4)	0.75	-0.5 (-3.5 to 2.4)	0.72
Emotional functioning score	75.1 (19.1)	77.9 (16.4)	-2.8 (-6.0 to 0.4)	0.09	-2.8 (-6.0 to 0.4)	0.09
Social functioning score	81.4 (20.2)	83.7 (19.3)	-2.3 (-5.6 to 1.0)	0.17	-2.3 (-5.6 to 0.9)	0.16
School functioning score	75.6 (19.7)	76.4 (19.7)	-0.9 (-4.3 to 2.5)	0.62	-0.8 (-4.1 to 2.4)	0.61
Psychosocial health summary score	77.4 (16.4)	79.4 (15.5)	-2.0 (-4.8 to 0.8)	0.17	-2.0 (-4.7 to 0.8)	0.16
Physical health summary score	87.2 (17.6)	87.7 (17.1)	-0.5 (-3.4 to 2.4)	0.75	-0.5 (-3.5 to 2.4)	0.72

Continued



Table 5 Continued

Outcome	High-DHA diet mean (SD) N=291	Standard-DHA diet mean (SD) N=313	Unadjusted mean difference (95% CI)	Unadjusted p Value	Adjusted mean difference (95% CI)*	Adjusted p Value*
Total score	80.8 (15.2)	82.2 (14.4)	-1.5 (-4.1 to 1.1)	0.27	-1.5 (-4.0 to 1.1)	0.26
Number (%) of children who repeated a school year††	20 (6.7)	12 (3.8)	1.8 (0.8 to 4.0)	0.17	1.7 (0.8 to 3.7)	0.18

Values are mean (SD) and treatment effects are mean difference based on imputed data unless otherwise indicated.

*Adjusted for sex, birth weight (<1250 or ≥1250 g) and recruiting centre.

†Measures executive function; the mean (SD) score is 50 (10); a scale score or index greater than 64 is clinically indicative of dysfunction.

‡Measures Diagnostic and Statistical Manual of Mental Disorders version IV—defined symptoms of Attention Deficit Hyperactivity Disorder; the mean (SD) score is 50 (10), range 40–90; a normal score is less than 60; the elevated range (indicating more concerns than typical) is 60–69; a very elevated score (indicating many more concerns than typical) is greater than or equal to 70.

§Measures Behaviour: the normal emotional symptoms score range is 0–3; a score greater than 3 is indicative of dysfunction. The normal conduct problem score range is 0–2; a score greater than 2 is indicative of dysfunction. The normal hyperactivity score range is 0–5; a score greater than 5 is indicative of dysfunction. The normal peer problem score range is 0–2; a score greater than 2 is indicative of dysfunction. The normal prosocial behaviour score range is 6–10; a score less than 6 is indicative of dysfunction. The normal total difficulties score range is 0–13; a total difficulties score greater than 13 is indicative of dysfunction.

¶Measures general health status and health-related quality of life; a score of 1 indicates perfect health.

**Measures health-related quality of life; higher scores indicate a better health-related quality of life.

††Treatment effects are relative risk based on imputed data.

ADHD, Attention Deficit Hyperactivity Disorder; BRIEF, Behaviour Rating Inventory of Executive Functioning; DHA, docosahexaenoic acid.

In secondary outcomes, there was a significant sex by treatment interaction effect in the Metacognition index ($p=0.03$) and Global Executive composite score ($p=0.04$) of the BRIEF parent report questionnaire. The Metacognition index assesses the ability to initiate, plan, organise, self-monitor and sustain working memory and the Global Executive composite is a summary score incorporating all the BRIEF clinical scales; scores >64 are indicative of a potential clinical problem. While both groups achieved scores in the normal range, girls in the high-DHA group scored significantly higher in both the Metacognition index and Global Executive composite compared with the standard-DHA group (see web appendix B).

There was no significant sex by treatment interaction effect for the total difficulties scale of the Strengths and Difficulties Questionnaire, or for any of the other scales except conduct problems ($p=0.003$). Both groups achieved a conduct problems score in the normal range (scores >3 are indicative of dysfunction), but girls in the high-DHA group scored significantly higher compared with girls in the standard-DHA group (see web appendix B). Subgroup analyses by sex for all primary and secondary outcomes are reported in web appendix A and B.

Subgroup analysis by randomisation strata—birth weight <1250 or ≥1250 g

There was no evidence of effect measure modification by birthweight strata for any outcome. Web appendices C and D show primary and secondary outcomes by birthweight strata.

DISCUSSION

Principal findings

Our data indicate that supplementing enteral feeds with DHA at ≈1% of total fatty acids from within the first week of life to 40 weeks' CA in children born at less than 33 weeks' gestation did not benefit IQ, attention, executive function, behaviour, visual-spatial perceptual skills, educational progress and quality of life at 7 years' CA compared with a standard-DHA diet (≈0.35% total fatty acids).

In prespecified subgroup analyses, parent-reported assessments indicated that girls in the high-DHA group had poorer executive function and more behavioural problems than girls in the standard-DHA group. The differences found may be due to chance, particularly given the high number of statistical comparisons, or may indicate a true underlying adverse effect of supplementation. Women in the high-DHA group were more likely to correctly guess their group allocation,⁶ so it is also possible that they had higher expectations of their children compared with women in the standard-DHA group. It is important to note that these results are inconsistent with those from direct assessment of executive function (the Rey Complex Figure and Fruit Stroop Test), which did not demonstrate differences between groups. There was no effect of birth weight (<1250 or ≥1250 g) on any outcome.

Strengths and limitations

This 7-year follow-up of our randomised controlled trial of preterm born children is the only study to evaluate the effect a diet that provides the estimated in utero accretion rate of DHA in infancy has on neurodevelopmental outcomes in the early school years. The strengths of the study include the sample size which was large enough to detect a four-point difference in Full Scale IQ if it existed, the low risk of bias achieved through blinding of research personnel, outcome assessors and participants (apart from the 12 families that requested to be unblinded), and the minimal rate of attrition. The follow-up had clinically relevant prespecified primary and secondary outcomes and a prespecified analysis plan. Robust objective assessments of neurodevelopmental outcomes were undertaken by psychologists after extensive training and ongoing auditing. Our study was a pragmatic trial involving five Australian perinatal centres suggesting generalisability of the results to the wider preterm infant population in developed countries. However, the study relied on the infant achieving full enteral feeds to receive the full dose of DHA delivered either through human milk or infant formula. DHA is well absorbed by preterm infants¹⁵ and this was reflected in the increase in the erythrocyte membrane phospholipid DHA status of infants in the treatment group.¹⁶ The erythrocyte DHA status achieved in the high-DHA group was greater than previous trials that used lower DHA doses,¹⁷ although it did not quite reach our target level.¹⁸ This may be due to the variation of DHA in breast milk, maternal compliance and delays in achieving the full DHA dose from intolerance to enteral feeds.

A limitation of the study was not including a teacher assessment of the child's behaviour as the diagnostic accuracy of both the Strengths and Difficulties Questionnaire and the BRIEF is superior when both parent and teacher reports are used.^{19 20}

Comparison with other studies

Early DHA intervention trials in preterm infants compared infants that received formula supplemented with DHA with infants receiving formulas devoid of DHA. Benefits seen in the supplemented infants led to all preterm infant formula being supplemented with DHA at a dose comparable to the standard dose in our trial. There are only two trials of current clinical relevance, the DINO trial⁶ and that of Henriksen *et al.*^{5 21} In both these trials, DHA doses reflective of the estimated in utero accretion rate and inclusive of breast milk feeding were used.^{5 6 21} We reported previously that providing enteral feeds containing DHA at $\approx 1\%$ total fatty acids improved visual acuity at 4 months' CA,⁷ reduced cognitive delay, improved the neurodevelopment of girls and was strongly suggestive of improved neurodevelopment in infants born weighing <1250 g at 18 months' CA compared with a standard-DHA diet.⁶ The DINO results were consistent with the only other preterm infant trial of high-DHA compared with standard-DHA where

improvement in problem solving was demonstrated at 6 months' CA⁵ and in sustained attention at 20 months of age.²¹ However, their results need to be interpreted with caution due to the small sample size and large attrition.²¹

Of the earlier studies comparing DHA supplemented formula with formula containing no DHA, only one trial has assessed children beyond 18 months of age to determine cognitive effects of DHA supplementation in infancy.²² In that study, preterm infants were randomised to receive formula supplemented with DHA (0.5%) versus no DHA supplementation to 9 months post-term.²³ As with our study, they found no significant differences between groups in Full Scale IQ or any cognitive outcome measures at 10 years of age.²² In contrast to our study, girls who received the DHA supplemented formula showed greater reading and spelling skills than girls in the control group.²² Their results, however, need to be interpreted with caution because of the high risk of bias due to incomplete outcome data with 55% attrition at the 10-year follow-up.

In a follow-up of a subset of this DINO cohort at 3–5 years' CA, no differences in parent-reported behaviour were detected but the results were limited by the sample size ($n=125$).²⁴ However, the parental report of poorer executive function and conduct problems in girls who received a high-DHA diet is consistent with results found in the DHA to Optimize Mother Infant Outcome trial.²⁵ In that trial, women were supplemented with DHA during pregnancy and children were assessed at 4 years of age. Poorer scores on some but not all indices of parent-reported executive function and behaviour were found, although there was no evidence of effect modification by sex.²⁵ Executive function has not been assessed during childhood in preterm infant DHA supplementation studies. Given the possibility of poorer executive function and conduct problems we found in girls who received a high-DHA diet, it will be important to determine if there is evidence of a difference in later childhood or adolescence. It is possible that the potential differences found may reduce with age.²⁶

Biological and environmental factors interplay to influence cognitive development. In the long term, the effect of the family and environment may have a greater influence on cognitive outcomes.^{27–29} The most frequent indicator used for the family and environmental effect on cognitive outcomes in preterm infants has been maternal education level.²⁷ While a composite measure of socioeconomic status may provide a more discriminant indicator, maternal education has consistently been shown to be associated with cognitive achievement.²⁷ There were no differences in maternal education level attained between the high-DHA and standard-DHA groups in our 7-year follow-up and the education level was similar to the Australian average. Therefore, at least on this somewhat limited indicator of socioeconomic status, both groups had the same socioeconomic influences. A weakening of differences in

cognitive outcome between 18 months and early childhood was also seen in the ‘Caffeine for Apnoea of Prematurity’ trial where a cognitive benefit was found at 18 months, but by 5 years of age there was no difference.³⁰ Thus, the early benefits of specific neonatal interventions appear to wane in middle childhood, but this does not discount delayed effects.

Conclusions and policy implications

There is limited evidence that DHA supplementation given in the first months of life to preterm infants benefits school-aged outcomes. Our results indicate that provision of enteral feeds containing a DHA dose of $\approx 1\%$ of total fatty acids in the newborn period provides little evidence of long-term benefit.

Author affiliations

¹Women’s and Children’s Health Research Institute, North Adelaide, South Australia, Australia

²Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia

³School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, South Australia, Australia

⁴FOODplus Research Centre, The University of Adelaide, Adelaide, South Australia, Australia

⁵Clinical Sciences, The Murdoch Children’s Research Institute, Parkville, Victoria, Australia

⁶Department of Paediatrics, The University of Melbourne, Royal Children’s Hospital, Parkville, Victoria, Australia

⁷Department of Neonatal Medicine, Women’s and Children’s Hospital, North Adelaide, South Australia, Australia

⁸School of Population Health, The University of Adelaide, Adelaide, South Australia, Australia

⁹Department of Obstetrics and Gynaecology, The Royal Women’s Hospital, Parkville, Victoria, Australia

¹⁰Centre of Neonatal Research and Education, The University of Western Australia, Perth, Western Australia, Australia

¹¹King Edward Memorial Hospital and Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia

¹²Perinatal Research Centre, University of Queensland Centre for Clinical Research, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia

¹³Centre for Perinatal Medicine, Flinders Medical Centre and School of Medicine, Flinders University, Adelaide, South Australia, Australia

Acknowledgements The authors thank the families who generously participated in this study. Steering committee—CTC, MM, RAG, AJM, PR, TRS, PJA, LWD, PGD, PBC, NPF, JEM, A O’Grady (study coordinator, Women’s and Children’s Health Research Institute, Adelaide). Coordinating centre—staff at the Women’s and Children’s Health Research Institute, Adelaide, Australia. Data management—staff at the Data Management & Analysis Centre, School of Population Health, The University of Adelaide, Adelaide, Australia. Mortality committee—J Lipsett and D Baulderstone, Women’s and Children’s Hospital, Adelaide, Australia. DINO Trial collaborating centres—the following investigators and research staff contributed to the 7-year follow-up of DINO trial participants. Study sites are listed in order of the number of children they enrolled. Women’s and Children’s Hospital, Adelaide, South Australia: AJM. King Edward Memorial Hospital, Perth, Western Australia: JEM, NPF, KS, C Kok, L Peake, C Campbell and the PROJECT K.I.D.S team. Royal Women’s Hospital, Victoria: LWD, PJA, PGD, C Callanan, M McDonald, C Molloy, S Stokes. Royal Brisbane and Women’s Hospital and the Perinatal Research Centre, University of Queensland Centre for Clinical Research, Queensland: PBC. Flinders Medical Centre, South Australia: SAM. This is an IMPACT (Interdisciplinary Maternal and Perinatal Australasian Clinical Trials) Network endorsed study.

Contributors CTC, RAG, PJA, AJM, TRS, PR, LWD, PGD, PBC, KS, SAM and MM were involved in the development and design of the trial. All authors were involved in the conduct of the trial. CTC drafted the manuscript. All authors critically revised and edited the manuscript and approved the final submitted version. TRS carried out the statistical analyses. All other authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CTC and MM are the guarantors of this study.

Funding This work was supported by a 5-year project grant from the National Health and Medical Research Council (NHMRC), Australia (ID 508003) and Mead Johnson Nutrition. CTC is supported through a MS McLeod Postdoctoral Research Fellowship (MS McLeod Research Fund, Women’s and Children’s Hospital Research Foundation); NHMRC Fellowships support RAG (Senior Principal Research Fellow APP1046207), PJA (Senior Research Fellow APP628371), PGD (Practitioner Fellow APP1059111), PBC (Practitioner Fellow APP511117), MM (Principal Research Fellow APP1061704).

Competing interests All authors have completed the ICMJE uniform disclosure at www.icmje.org/coi_disclosure.pdf and declare: financial support for the submitted work from the National Health and Medical Research Council (NHMRC) Australia for the original trial (ID 250322) and 7-year follow-up study (ID 508003) and from Mead Johnson Nutrition for the 7-year follow-up study. Treatment and placebo capsules for the original trial were donated by Clover Corporation and infant formula was donated by Mead Johnson Nutrition and Nutricia Australasia. CTC, RAG and MM have received non-financial support from Clover Corporation and Nestle Nutrition for research outside that of the submitted work. RAG serves on a scientific advisory board for Fonterra; MM serves on scientific advisory boards for Nestle, Fonterra and Nutricia. Associated honoraria for RAG and MM are paid to their respective institutions to support conference travel and continuing education for postgraduate students and early career researchers. MM and RAG, through the Women’s and Children’s Health Research Institute, have a patent pending “Methods and compositions for promoting the neurological development of an infant.” KS received honoraria from the Nestle Nutrition Institute and grants from Medela Switzerland.

Ethics approval This study was approved by each collaborating centre: Flinders Medical Centre—Southern Adelaide Clinical Human Research Ethics Committee (Application 221.11); King Edward Memorial Hospital—Women and Newborn Health Service Ethics Committee (Registration Number 1832/EW); The Royal Brisbane and Women’s Hospital—Queensland Children’s Health Services (RCH) Human Research Ethics Committee (Reference number HREC/11/QRCH/7) and The University of Queensland Medical Research Ethics Committee (Project number 2012000021); The Royal Women’s Hospital—Royal Women’s Hospital Human Research Ethics Committee (Project 11/05); The Women’s and Children’s Hospital—Children Youth and Women’s Health Service Research Ethics Committee (REC2015/11/10).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Kerr-Wilson CO, Mackay DF, Smith GC, *et al*. Meta-analysis of the association between preterm delivery and intelligence. *J Public Health (Oxford)* 2012;34:209–16.
2. Innis SM. Dietary (n-3) fatty acids and brain development. *J Nutr* 2007;137:855–9.
3. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. *J Pediatr* 1992;120:S129–38.
4. Lapillonne A, Groh-Wargo S, Gonzalez CH, *et al*. Lipid needs of preterm infants: updated recommendations. *J Pediatr* 2013;162:S37–47.
5. Henriksen C, Haugholt K, Lindgren M, *et al*. Improved cognitive development among preterm infants attributable to early

- supplementation of human milk with docosahexaenoic acid and arachidonic acid. *Pediatrics* 2008;121:1137–45.
6. Makrides M, Gibson RA, McPhee AJ, *et al.* Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. *JAMA* 2009;301:175–82.
 7. Smithers LG, Gibson RA, McPhee A, *et al.* Higher dose of docosahexaenoic acid in the neonatal period improves visual acuity of preterm infants: results of a randomized controlled trial. *Am J Clin Nutr* 2008;88:1049–56.
 8. Hack M, Taylor HG, Drotar D, *et al.* Poor predictive validity of the bayley scales of infant development for cognitive function of extremely low birth weight children at school age. *Pediatrics* 2005;116:333–41.
 9. Roberts G, Anderson PJ, Doyle LW; Group tVICS. The stability of the diagnosis of developmental disability between ages 2 and 8 in a geographic cohort of very preterm children born in 1997. *Arch Dis Child* 2010;95:786–90.
 10. Wilson-Ching M, Pascoe L, Doyle LW, *et al.* Effects of correcting for prematurity on cognitive test scores in childhood. *J Paediatr Child Health* 2014;50:182–8.
 11. Manly T, Robertson IH, Anderson V, *et al.* *TEA-Ch: The test of everyday attention for children*. Bury St Edmunds, England: Thames Valley Test Company Ltd, 1999.
 12. Wilson-Ching M, Molloy CS, Anderson VA, *et al.* Attention difficulties in a contemporary geographic cohort of adolescents born extremely preterm/extremely low birth weight. *JINS* 2013;19:1097–108.
 13. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. *Stat Methods Med Res* 2007;16:219–42.
 14. Rubin DB. *Multiple imputation for nonresponse in surveys*. New York: John Wiley & Sons, 1987.
 15. Carnielli VP, Simonato M, Verlato G, *et al.* Synthesis of long-chain polyunsaturated fatty acids in preterm newborns fed formula with long-chain polyunsaturated fatty acids. *Am J Clin Nutr* 2007;86:1323–30.
 16. Smithers LG, Gibson RA, McPhee A, *et al.* Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial. *Prostaglandins Leukot Essent Fatty Acids* 2008;79:141–6.
 17. Clandinin MT, Van Aerde JE, Parrott A, *et al.* Assessment of the efficacious dose of arachidonic and docosahexaenoic acids in preterm infant formulas: fatty acid composition of erythrocyte membrane lipids. *Pediatr Res* 1997;42:819–25.
 18. Makrides M. DHA supplementation during the perinatal period and neurodevelopment: Do some babies benefit more than others? *Prostaglandins Leukot Essent Fatty Acids* 2013;88:87–90.
 19. Johnson S, Hollis C, Marlow N, *et al.* Screening for childhood mental health disorders using the Strengths and Difficulties Questionnaire: the validity of multi-informant reports. *Dev Med Child Neurol* 2014;56:453–9.
 20. Sullivan JR, Riccio CA. Diagnostic group differences in parent and teacher ratings on the BRIEF and Conners' Scales. *J Atten Disord* 2007;11:398–406.
 21. Westerberg AC, Schei R, Henriksen C, *et al.* Attention among very low birth weight infants following early supplementation with docosahexaenoic and arachidonic acid. *Acta Paediatr* 2011;100:47–52.
 22. Isaacs EB, Ross S, Kennedy K, *et al.* 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy. *Pediatrics* 2011;128:e890–8.
 23. Fewtrell MS, Abbott RA, Kennedy K, *et al.* Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants. *J Pediatr* 2004;144:471–9.
 24. Smithers LG, Collins CT, Simmonds LA, *et al.* Feeding preterm infants milk with a higher dose of docosahexaenoic acid than that used in current practice does not influence language or behavior in early childhood: a follow-up study of a randomized controlled trial. *Am J Clin Nutr* 2010;91:628–34.
 25. Makrides M, Gould JF, Gawlik NR, *et al.* Four-year follow-up of children born to women in a randomized trial of prenatal DHA supplementation. *JAMA* 2014;311:1802–4.
 26. Mulder H, Pitchford NJ, Hagger MS, *et al.* Development of executive function and attention in preterm children: a systematic review. *Dev Neuropsychol* 2009;34:393–421.
 27. Wong HS, Edwards P. Nature or nurture: a systematic review of the effect of socio-economic status on the developmental and cognitive outcomes of children born preterm. *Matern Child Health J* 2013;17:1689–700.
 28. Schneider LA, Burns NR, Giles LC, *et al.* Cognitive abilities in preterm and term-born adolescents. *J Pediatr* 2014;165:170–7.
 29. Fawer CL, Besnier S, Forcada M, *et al.* Influence of perinatal, developmental and environmental factors on cognitive abilities of preterm children without major impairments at 5 years. *Early Hum Dev* 1995;43:151–64.
 30. Schmidt B, Anderson PJ, Doyle LW, *et al.* Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. *JAMA* 2012;307:275–82.
 31. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. *Stat Med* 1998;17:407–29.

Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial

Carmel T Collins, Robert A Gibson, Peter J Anderson, Andrew J McPhee, Thomas R Sullivan, Jacqueline F Gould, Philip Ryan, Lex W Doyle, Peter G Davis, Judy E McMichael, Noel P French, Paul B Colditz, Karen Simmer, Scott A Morris and Maria Makrides

BMJ Open 2015 5:
doi: 10.1136/bmjopen-2014-007314

Updated information and services can be found at:
<http://bmjopen.bmj.com/content/5/3/e007314>

These include:

Supplementary Material

Supplementary material can be found at:
<http://bmjopen.bmj.com/content/suppl/2015/03/18/bmjopen-2014-007314.DC1.html>

References

This article cites 29 articles, 11 of which you can access for free at:
<http://bmjopen.bmj.com/content/5/3/e007314#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Nutrition and metabolism](#) (174)
[Paediatrics](#) (309)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>